Several dermatoses, including psoriasis, atopic dermatitis, and rosacea, alter the expression
of the innate immune effector human cathelicidin antimicrobial peptide (CAMP). To …

In the course of our studies on non-peptide bradykinin (BK) B 2 receptor ligands, it was
suggested that the 4-substituent of the quinoline ring may play a critical role in determining …

A novel class of potent, selective, and orally active non-peptide bradykinin (BK) B 2 receptor
antagonists were designed and synthesized starting from 8-benzyloxyimidazo[1,2-a]…

Mycosis fungoides ( MF ) starts as an indolent disease, progresses from a patch stage to
confluent plaques and ultimately develops skin tumors. Tumor‐associated macrophages ( TAM …

In recent articles we reported the identification of a series of 8-[[2,6-dichloro-3-[N-methyl-N-[(E)-(substituted)acryloylglycyl]amino]benzyl]oxy]-2-methylimidazo[1,2-a]pyridines
as the first …

Recently we reported on overcoming the species difference of our first orally active non-peptide
bradykinin (BK) B 2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-…

Background Tumor-associated M2 macrophages (TAMs) produce chemokines that affect
the formation of cutaneous T-cell lymphoma (CTCL) by stromal factors. Since IFNs are an …

Medicine, Sendai, Japan (2013-1-521), and all patients gave written informed consent. The
antibodies and antigen retrieval methods used are described in Supplementary Table S3 …

1 An orally active, nonpeptide bradykinin (BK) B 2 receptor antagonist, FR173657 (E)‐3‐(6‐acetamido‐3‐pyridyl)‐N‐[N‐[2‐4‐dichloro‐3‐[(2‐methyl‐8‐quinolinyl)
oxymethyl]phenyl]‐N‐…

Introduction of nitrogen-containing heteroaromatic groups at the 4-position of the quinoline
moiety of our non-peptide B 2 receptor antagonists resulted in enhancing binding affinities for …